Your session is about to expire
← Back to Search
Coagulation Factor
A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Phase 2
Waitlist Available
Research Sponsored by CSL Behring
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
No Placebo-Only Group
Summary
Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.
Eligible Conditions
- Factor XIII Deficiency
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incremental Recovery
Secondary study objectives
Adverse Events
Laboratory Safety Parameters
Vital Signs
Side effects data
From 2011 Phase 3 trial • 41 Patients • NCT0088574224%
Upper respiratory infection
12%
Fever
12%
Cough
10%
Fall
10%
Nasal congestion
7%
Vomiting
7%
Abrasions
7%
Bruising of thigh
7%
Sore throat
7%
Acne
7%
Thrombin-antithrombin III complex increased
7%
Wrist pain
7%
Headache
7%
Rhinorrhea
2%
Urinary tract infection
2%
Appendicitis
2%
Traumatic chest injury NOS
2%
Chest pain with radiation to left arm
2%
Hip injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
FXIII
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: FXIIIExperimental Treatment1 Intervention
All subjects treated with Factor XIII Concentrate (Human) (FXIII)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FXIII Concentrate (Human)
2009
Completed Phase 3
~60
Find a Location
Who is running the clinical trial?
CSL BehringLead Sponsor
200 Previous Clinical Trials
1,205,088 Total Patients Enrolled
3 Trials studying Factor XIII Deficiency
174 Patients Enrolled for Factor XIII Deficiency
Program Director, Clinical R&DStudy DirectorCSL Behring
12 Previous Clinical Trials
874 Total Patients Enrolled
2 Trials studying Factor XIII Deficiency
102 Patients Enrolled for Factor XIII Deficiency